Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: Implications for clinical practice.

Oey, O; Ghaffari, M; Li, JJ; Hosseini-Beheshti, E

Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: Implications for clinical practice.

Oey, O Ghaffari, M Li, JJ Hosseini-Beheshti, E

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Crit Rev Oncol Hematol, 2021, 167, pp. 103495
Issue Date:: 2021-11

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted versionAdobe PDF (463.3 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Oey, O
dc.contributor.author	Ghaffari, M
dc.contributor.author	Li, JJ
dc.contributor.author	Hosseini-Beheshti, E
dc.date.accessioned	2023-01-18T05:30:36Z
dc.date.available	2021-09-08
dc.date.available	2023-01-18T05:30:36Z
dc.date.issued	2021-11
dc.identifier.citation	Crit Rev Oncol Hematol, 2021, 167, pp. 103495
dc.identifier.issn	1040-8428
dc.identifier.issn	1879-0461
dc.identifier.uri	http://hdl.handle.net/10453/165137
dc.description.abstract	Extracellular vesicles (EV) are cell-derived lipid bilayer-delimited structures providing an important means of intercellular communication. Recent studies have shown that EV, particularly exosomes and large-oncosomes contain miRNA and proteins crucial in prostate cancer (PCa) progression, metastasis and treatment resistance. This includes not just EV released from PCa cells, but also from other cells in the tumor microenvironment. PCa patient derived EV have a unique composition compared to healthy and benign prostatic diseases. As such, EV show promise as diagnostic liquid biopsy biomarkers, both as an adjunct and alternative to the invasive current gold-standard. EV could also be utilized to stratify patients' risk and predict response to hormonal, chemo, immune- and targeted therapy, which will direct future treatment decisions in PCa. We present a summary of the current evidence on the role of EV in PCa and the application of EV in PCa diagnosis and treatment to optimize patient outcomes.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation	http://purl.org/au-research/grants/nhmrc/1120249
dc.relation.ispartof	Crit Rev Oncol Hematol
dc.relation.isbasedon	10.1016/j.critrevonc.2021.103495
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Exosomes
dc.subject.mesh	Extracellular Vesicles
dc.subject.mesh	Humans
dc.subject.mesh	Liquid Biopsy
dc.subject.mesh	Male
dc.subject.mesh	MicroRNAs
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Humans
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	MicroRNAs
dc.subject.mesh	Male
dc.subject.mesh	Exosomes
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Extracellular Vesicles
dc.subject.mesh	Liquid Biopsy
dc.title	Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: Implications for clinical practice.
dc.type	Journal Article
utslib.citation.volume	167
utslib.location.activity	Netherlands
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	open_access	*
dc.date.updated	2023-01-18T05:30:35Z
pubs.publication-status	Published
pubs.volume	167

Abstract:

Extracellular vesicles (EV) are cell-derived lipid bilayer-delimited structures providing an important means of intercellular communication. Recent studies have shown that EV, particularly exosomes and large-oncosomes contain miRNA and proteins crucial in prostate cancer (PCa) progression, metastasis and treatment resistance. This includes not just EV released from PCa cells, but also from other cells in the tumor microenvironment. PCa patient derived EV have a unique composition compared to healthy and benign prostatic diseases. As such, EV show promise as diagnostic liquid biopsy biomarkers, both as an adjunct and alternative to the invasive current gold-standard. EV could also be utilized to stratify patients' risk and predict response to hormonal, chemo, immune- and targeted therapy, which will direct future treatment decisions in PCa. We present a summary of the current evidence on the role of EV in PCa and the application of EV in PCa diagnosis and treatment to optimize patient outcomes.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/165137